Value-Based Cancer Care Issues


February 2017, Vol 8, No 1

New Value Model Incorporates Long-Term Adverse Effects of Cancer Drugs

Chase Doyle

Value-Based Care

A new economic model suggests that overall survival and drug toxicity profiles are insufficient for assessing the value of a drug. According to a study that incorporated late adverse events in advanced Hodgkin lymphoma, a more comprehensive benefit-to-risk ratio of a drug requires an understanding of its long-term health implications, said Ohad Oren, MD, Pennsylvania Hospital, University of Pennsylvania, Philadelphia, at the 2016 American Society of Hematology meeting. [ Read More ]